A novel mechanism for anxiety behaviors, including a previously unrecognized inhibitory brain signal, may inspire new strategies for treating psychiatric disorders, University of Chicago researchers report.

By testing the controversial role of a gene called Glo1 in anxiety, scientists uncovered a new inhibitory factor in the brain: the metabolic by-product methylglyoxal. The system offers a tantalizing new target for drugs designed to treat conditions such as anxiety disorder, epilepsy, and sleep disorders.

The study, published in the Journal of Clinical Investigation, found that animals with multiple copies of the Glo1 gene were more likely to exhibit anxiety-like behavior in laboratory tests. Further experiments showed that Glo1 increased anxiety-like behavior by lowering levels of methylglyoxal (MG). Conversely, inhibiting Glo1 or raising MG levels reduced anxiety behaviors.

Full story of anxiety disorder gene at Science Daily

Photos courtesy of and copyright stock.xchng, http://www.sxc.hu/

Sharia stood immobile in front of the television, transfixed by its images, unaware of the world around her. Her family called her name over and over again, but she did not respond. It was that moment when they knew something was wrong.

Initially, they thought it was a hearing problem. When they found nothing wrong, they decided to take 2-year-old Sharia to a specialist at an early detection center in 2009.

"Within five minutes of looking at Sharia, (the specialist) said that she has autism," said Sharia’s father, Fawad Siddiqui. "A very clear case of it."

Siddiqui, 38, and his wife, Ayza Sheikh, were under the impression that Sharia was simply a late talker. Originally from Pakistan, the Siddiquis had no relatives to advise them on their first child.

Speech, occupational and behavior therapies helped some. But Sharia still struggled with communication.

Then, in 2010, Apple’s iPad was released.

Full story of iPad helps kids with autism at CNN Tech

Photos courtesy of and copyright stock.xchng, http://www.sxc.hu/

Neuroscientist Patrik Verstreken, associated with VIB and KU Leuven, succeeded in undoing the effect of one of the genetic defects that leads to Parkinson’s using vitamin K2. His discovery gives hope to Parkinson’s patients.

This research was done in collaboration with colleagues from Northern Illinois University (US) and was recently published in the journal Science.

"It appears from our research that administering vitamin K2 could possibly help patients with Parkinson’s. However, more work needs to be done to understand this better," says Patrik Verstreken.

Malfunctioning power plants are at the basis of Parkinson’s.

If we looked at cells as small factories, then mitochondria would be the power plants responsible for supplying the energy for their operation. They generate this energy by transporting electrons. In Parkinson’s patients, the activity of mitochondria and the transport of electrons have been disrupted, resulting in the mitochondria no longer producing sufficient energy for the cell. This has major consequences as the cells in certain parts of the brain will start dying off, disrupting communication between neurons. The results are the typical symptoms of Parkinson’s: lack of movement (akinesia), tremors and muscle stiffness.

Full story of hope for parkinson’s patients at Science Daily

Photos courtesy of and copyright stock.xchng, http://www.sxc.hu/

Babies born to women with sensitivity to gluten appear to be at increased risk for certain psychiatric disorders later in life, according to research by scientists at Karolinska Institutet in Sweden and Johns Hopkins Children’s Center in Baltimore.

The team’s findings, published ahead of print on April 25 in The American Journal of Psychiatry, add to a growing body of evidence that many "adult" diseases may take root before and shortly after birth.

"Lifestyle and genes are not the only factors that shape disease risk, and factors and exposures before, during and after birth can help pre-program much of our adult health," said investigator Robert Yolken, M.D., a neuro-virologist at Johns Hopkins Children’s Center. "Our study is an illustrative example suggesting that a dietary sensitivity before birth could be a catalyst in the development of schizophrenia or a similar condition 25 years later."

Full story of schizophrenia risk in children at Science Daily

Photos courtesy of and copyright stock.xchng, http://www.sxc.hu/

Using Facebook and other social networking sites can negatively affect teenagers’ treatment for substance use disorders, a new study suggests.

Researchers administered a 20-question survey to 37 teens who were receiving substance abuse treatment at a behavioral health center in Los Angeles. Most reported marijuana as their drug of choice, followed by Ecstasy and methamphetamine, Psychiatric Times reports.

Almost all of the teens engaged in online social networking, with the majority using Facebook. While 44 percent of the teens said they posted drug-related content on the sites, 94 percent said their friends did, and 97 percent said their social networking friends used drugs.

Full story on substance abuse related to Facebook at Drugfree.org

Photos courtesy of and copyright stock.xchng, http://www.sxc.hu/